Variation Compass
How SFDA, the EU, the UK and the US FDA classify the same post-approval change, with the governing clause.
Open91 items
SFDA · EU · US FDA · WHO
Regulatory requirements compared
SFDA, EU, US FDA and WHO requirements quoted verbatim, with section references and links to the official documents. For regulatory affairs and pharmacovigilance.
- Authorities compared
- 4
- Authorities monitored
- 6
- Verbatim excerpts
- 284
- SFDA variation items mapped
- 91
Regulatory affairs
Post-approval changes, stability, bioequivalence, document changes and product registers.
Bioequivalence & biowaivers
Study design, acceptance limits, narrow therapeutic index and highly variable drugs, biowaivers.
Open162 excerpts
Stability testing & climatic zones
Storage conditions, batches, shelf life, extrapolation and labelling statements.
Open122 excerpts
Regulatory radar
New, revised and withdrawn documents from each authority's index; changes to the documents quoted in the comparisons.
Registered medicines
Products listed by SFDA, US FDA, EMA and Health Canada per active substance, with SFDA, NADAC and NHS Drug Tariff prices, authorised indications and WHO EML status.
Pharmacovigilance
Safety signals and local literature.
Safety signals
PRAC signal assessments, US FDA safety-related labeling changes and MHRA Drug Safety Update articles by active substance, with the PRAC-recommended SmPC and PL wording.
Open5,815 entries
Local literature
Articles in 35 Saudi and Gulf journals by active substance, for local literature screening; case reports and NLM adverse-effect indexing marked.
Open5,447 articles
Conventions
Verbatim text
Excerpts are quoted as published, with the section number; they are not paraphrased.
Official source
Each excerpt links to the authority's document; the official text prevails.
Status
Drafts, superseded provisions and withdrawn documents are marked.
Updated